Search

Your search keyword '"De Guibert, Sophie"' showing total 10 results
Start Over Author "De Guibert, Sophie" Publisher wiley
10 results on '"De Guibert, Sophie"'

1. Remission after CAR T‐cell therapy: Do lymphoma patients recover a normal life?

Author

Perthus, Alya, primary, Colin, Fanny, additional, Charton, Emilie, additional, Anota, Amélie, additional, Lhomme, Faustine, additional, Manson, Guillaume, additional, De Guibert, Sophie, additional, Daufresne, Pierre, additional, Bellec, Adeline, additional, Le Bars, Laetitia, additional, De Barros, Sandra, additional, Ysebaert, Loïc, additional, Merceur, Marianne, additional, Cogné, Mélanie, additional, Lamy De La Chapelle, Thierry, additional, Houot, Roch, additional, and Moignet, Aline, additional

Published
2024
Full Text
View/download PDF

2. Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma

Author

Oluwole, Olalekan O., primary, Bouabdallah, Krimo, additional, Muñoz, Javier, additional, De Guibert, Sophie, additional, Vose, Julie M., additional, Bartlett, Nancy L., additional, Lin, Yi, additional, Deol, Abhinav, additional, McSweeney, Peter A., additional, Goy, Andre H., additional, Kersten, Marie José, additional, Jacobson, Caron A., additional, Farooq, Umar, additional, Minnema, Monique C., additional, Thieblemont, Catherine, additional, Timmerman, John M., additional, Stiff, Patrick, additional, Avivi, Irit, additional, Tzachanis, Dimitrios, additional, Kim, Jenny J., additional, Bashir, Zahid, additional, McLeroy, Jeff, additional, Zheng, Yan, additional, Rossi, John M., additional, Johnson, Lisa, additional, Goyal, Lovely, additional, and van Meerten, Tom, additional

Published
2021
Full Text
View/download PDF

3. Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (FILO)

Author

Godet, Sophie, primary, Protin, Caroline, additional, Dupuis, Jehan, additional, Dartigeas, Caroline, additional, Bastie, Jean-Noël, additional, Herbaux, Charles, additional, Leblond, Véronique, additional, de Guibert, Sophie, additional, Ghez, David, additional, Brion, Annie, additional, Ysebaert, Loïc, additional, Delmer, Alain, additional, and Quinquenel, Anne, additional

Published
2017
Full Text
View/download PDF

4. Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group

Author

Michallet, Anne-Sophie, primary, Campidelli, Arnaud, additional, Lequeu, Helene, additional, Dilhuydy, Marie-Sarah, additional, Tournilhac, Olivier, additional, Fornecker, Luc-Matthieu, additional, Dupuis, Jehan, additional, Cymbalista, Florence, additional, De Guibert, Sophie, additional, Delmer, Alain, additional, Vilque, Jean-Pierre, additional, Ghez, David, additional, Leblond, Veronique, additional, Subtil, Fabien, additional, Feugier, Pierre, additional, and Ysebaert, Loic, additional

Published
2017
Full Text
View/download PDF

5. A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma

Author

Coiffier, Bertrand, primary, Thieblemont, Catherine, additional, de Guibert, Sophie, additional, Dupuis, Jehan, additional, Ribrag, Vincent, additional, Bouabdallah, Réda, additional, Morschhauser, Franck, additional, Navarro, Robert, additional, Le Gouill, Steven, additional, Haioun, Corinne, additional, Houot, Roch, additional, Casasnovas, Olivier, additional, Holte, Harald, additional, Lamy, Thierry, additional, Broussais, Florence, additional, Payrard, Sandrine, additional, Hatteville, Laurence, additional, and Tilly, Hervé, additional

Published
2016
Full Text
View/download PDF

6. Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no‐treatment study

Author

Loschi, Michael, primary, Porcher, Raphael, additional, Barraco, Fiorenza, additional, Terriou, Louis, additional, Mohty, Mohamad, additional, de Guibert, Sophie, additional, Mahe, Beatrice, additional, Lemal, Richard, additional, Dumas, Pierre‐Yves, additional, Etienne, Gabriel, additional, Jardin, Fabrice, additional, Royer, Bruno, additional, Bordessoule, Dominique, additional, Rohrlich, Pierre Simon, additional, Fornecker, Luc Mathieu, additional, Salanoubat, Celia, additional, Maury, Sebastien, additional, Cahn, Jean‐Yves, additional, Vincent, Laure, additional, Sene, Thomas, additional, Rigaudeau, Sophie, additional, Nguyen, Stephanie, additional, Lepretre, Anne‐Claire, additional, Mary, Jean‐Yves, additional, Corront, Bernadette, additional, Socie, Gerard, additional, and Peffault de Latour, Regis, additional

Published
2016
Full Text
View/download PDF

10. Early versus late intensification for patients with high-risk Hodgkin lymphoma-3 cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation: five-year results of a randomized trial on behalf of the GOELAMS Group.

Author

Arakelyan N, Berthou C, Desablens B, de Guibert S, Delwail V, Moles MP, Quittet P, Jais JP, Colonna P, and Andrieu JM

Subjects
Adult, Bleomycin therapeutic use, Combined Modality Therapy, Dacarbazine therapeutic use, Doxorubicin therapeutic use, Etoposide therapeutic use, Female, Hodgkin Disease drug therapy, Hodgkin Disease radiotherapy, Humans, Male, Methylprednisolone administration & dosage, Prednisone therapeutic use, Treatment Outcome, Vinblastine therapeutic use, Vincristine therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Hematopoietic Stem Cell Transplantation, Hodgkin Disease therapy, Lymphatic Irradiation
Abstract

Background: The 5-year freedom from treatment failure (FFTF) rate, with treatment failure defined as the lack of post-treatment complete remission (CR), recurrence, or death, ranges from 60% to 70% after 6 to 8 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), which is the reference treatment for patients with advanced Hodgkin lymphoma (HL). In this randomized, phase 2 study, the authors tested 2 intensive chemotherapy regimens in 158 patients with clinical stage (CS) IIB through IV HL accompanied by high-risk factors who were recruited between May 1997 and December 2004., Methods: High-risk CS IIB, III, and IV were defined by the presence of > or =5 involved lymphoid areas, and/or a mediastinal mass ratio > or =0.45, and/or > or =2 extra lymph node sites affected by the disease (for CS IV). In Arm V, 82 patients received 3 courses of combined vindesine (5 mg/m(2)), doxorubicin (99 mg/m(2)), carmustine (140 mg/m(2)), etoposide (600 mg/m(2)), and methylprednisolone (600 mg/m(2)) (VABEM) followed by low-dose lymph node irradiation. In Arm A, 76 patients received 4 cycles of ABVD followed by myeloablative combined carmustine (300 mg/m(2)), etoposide (800 mg/m(2)), cytarabine (1600 mg/m(2)), and melphalan (140 mg/m(2)) and underwent autologous stem cell transplantation., Results: After 3 cycles of VABEM, the CR rate was 89% versus 60% after 4 cycles of ABVD. However, after the completion of treatment, the CR rates for Arms V and A were similar (89% and 88%, respectively). The 5-year FFTF rates for Arms V and A also were similar (79% and 75%, respectively) along with the 5-year overall survival rates (87% and 86%, respectively)., Conclusions: Early intensification (Arm V) and late intensification (Arm A) were equally effective for treating patients with high-risk/advanced HL.

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results